MCID: GLC003
MIFTS: 58

Glucose Intolerance

Categories: Metabolic diseases

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 12 29 55 6 44 15
Impaired Glucose Tolerance 73
Malabsorption of Glucose 12
Fatty Stool 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10603
ICD10 33 R73.03
MeSH 44 D018149
NCIt 50 C34646
SNOMED-CT 68 9414007
UMLS 73 C0271650

Summaries for Glucose Intolerance

MalaCards based summary : Glucose Intolerance, also known as impaired glucose tolerance, is related to abdominal obesity-metabolic syndrome 1 and fatty liver disease, nonalcoholic 1. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA Leucine 1 (UUA/G)), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Metformin and Saxagliptin have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and ovary, and related phenotypes are adipose tissue and endocrine/exocrine gland

Wikipedia : 76 Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with... more...

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 198)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome 1 31.4 SLC2A4 PPARG LEP INS ADIPOQ
2 fatty liver disease, nonalcoholic 1 30.8 RETN LEP INS ADIPOQ
3 polycystic ovary syndrome 30.5 SHBG LEP IRS1 INSR INS IGFBP1
4 fatty liver disease 30.3 LEPR LEP IRS1 INSR INS ADIPOQ
5 liver disease 30.3 ADIPOQ INS LEP LEPR
6 acromegaly 30.2 INS IGFBP1 IGF1 GHRL
7 myocardial infarction 30.2 ADIPOQ CRP GHRL INS RETN
8 gestational diabetes 30.1 SLC2A4 SHBG RETN RBP4 LEP IRS1
9 coronary heart disease 1 30.1 ADIPOQ CRP INS RETN
10 hyperthyroidism 30.0 SHBG LEP INS GHRL
11 hyperproinsulinemia 30.0 SHBG INS IGFBP1
12 sleep disorder 29.9 CRP INS LEP
13 hyperinsulinemic hypoglycemia 29.9 GCK INS INSR
14 insulin-like growth factor i 29.9 SHBG LEP IRS1 INSR INS IGFBP1
15 arteries, anomalies of 29.9 PPARG LEP INS CRP ADIPOQ
16 uremia 29.8 RETN LEP INS CRP
17 hyperinsulinism 29.8 SHBG LEP INSR INS IGFBP1 IGF1
18 turner syndrome 29.8 IGF1 IGFBP1 SHBG
19 insulinoma 29.7 GCG GCK INS
20 anovulation 29.7 SHBG LEP INS IGF1 CRP
21 hypoglycemia 29.7 GCG GCK INS INSR
22 sleep apnea 29.6 LEPR LEP INS IGF1 GHRL CRP
23 chronic kidney failure 29.6 LEP INS IGFBP1 IGF1 CRP ADIPOQ
24 hypertension, essential 29.5 RETN LEP INSR INS CRP ADRB3
25 hyperglycemia 29.3 PPARG LEP IRS1 INSR INS IGF1
26 lipid metabolism disorder 29.2 RETN RBP4 PPARG LEP INS CRP
27 nonalcoholic fatty liver disease 29.2 ADIPOQ RETN RBP4 PPARG LEP INS
28 diabetes mellitus 28.8 SLC2A4 SHBG RETN PPARG LEP IRS1
29 overnutrition 28.0 SLC2A4 SHBG RETN PPARG LEPR LEP
30 diabetes mellitus, noninsulin-dependent 27.9 SLC2A4 SHBG RETN RBP4 PPARG LEPR
31 body mass index quantitative trait locus 11 27.5 SLC2A4 SHBG RETN RBP4 PPARG LEPR
32 steatorrhea 11.4
33 mental retardation, skeletal dysplasia, and abducens palsy 11.2
34 lipodystrophy, familial partial, type 2 11.1
35 growth hormone insensitivity with immunodeficiency 11.1
36 aromatase deficiency 11.1
37 estrogen resistance 11.1
38 pancreatitis, hereditary 11.1
39 cystic fibrosis 10.4
40 malignant otitis externa 10.3 CRP INS
41 aging 10.2
42 mixed cell adenoma 10.2 IGF1 IRS1
43 lipodystrophy, congenital generalized, type 1 10.2 LEP INS ADIPOQ
44 idiopathic recurrent pericarditis 10.2 RETN LEP ADIPOQ
45 obesity-hypoventilation syndrome 10.2 RETN LEP ADIPOQ
46 nonalcoholic steatohepatitis 10.2 ADIPOQ INS LEP
47 secondary adrenal insufficiency 10.2 IGF1 INS
48 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.2 INSR INS IGF1
49 hyperuricemia 10.2 ADRB3 CRP INS
50 coronary artery aneurysm 10.2 ADIPOQ LEP RETN

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.27 ADIPOQ ADRB3 GHRL IGF1 INS INSR
2 endocrine/exocrine gland MP:0005379 10.25 ADIPOQ ADRB3 DPP4 GCK GHRL IGF1
3 cardiovascular system MP:0005385 10.22 ADIPOQ CRP IGF1 INS INSR IRS1
4 homeostasis/metabolism MP:0005376 10.22 ADIPOQ ADRB3 CRP DPP4 GCK GHRL
5 cellular MP:0005384 10.2 ADIPOQ IGF1 IGFBP1 INS INSR IRS1
6 growth/size/body region MP:0005378 10.15 ADIPOQ ADRB3 DPP4 GCK IGF1 INS
7 immune system MP:0005387 10.03 ADIPOQ CRP IGF1 IGFBP1 INS INSR
8 digestive/alimentary MP:0005381 9.98 GHRL INS INSR LEP LEPR RBP4
9 liver/biliary system MP:0005370 9.9 ADIPOQ GCK IGFBP1 INS INSR IRS1
10 muscle MP:0005369 9.65 ADIPOQ IGF1 INS INSR IRS1 LEP
11 renal/urinary system MP:0005367 9.28 ADIPOQ GCK IGF1 INS INSR LEP

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
2
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Not Applicable 361442-04-8 11243969
3
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
4
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 122320-73-4 77999
5
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
6
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6
7
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
8 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
10
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
11
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
12
Insulin Glargine Approved Phase 4,Phase 3,Phase 1,Not Applicable 160337-95-1
13
Insulin Aspart Approved Phase 4,Not Applicable 116094-23-6 16132418
14
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Not Applicable 133107-64-9
15
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068
16
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092
17
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
18
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3 5949-44-0
19
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
20
Testosterone enanthate Approved Phase 4,Phase 3 315-37-7 9416
21
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
22
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
23
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 141758-74-9 15991534
24
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
25
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
26
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
27
Bilberry Approved, Experimental Phase 4,Not Applicable
28
Hydroxychloroquine Approved Phase 4 118-42-3 3652
29
Pravastatin Approved Phase 4 81093-37-0 54687
30
Nebivolol Approved, Investigational Phase 4 99200-09-6, 152520-56-4, 118457-14-0 71301
31
Losartan Approved Phase 4,Phase 2,Not Applicable 114798-26-4 3961
32
Lisinopril Approved, Investigational Phase 4,Not Applicable 83915-83-7, 76547-98-3 5362119
33
Nateglinide Approved, Investigational Phase 4,Phase 3 105816-04-4 60026
34
Telmisartan Approved, Investigational Phase 4,Phase 2 144701-48-4 65999
35
Amlodipine Approved Phase 4 88150-42-9 2162
36
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
37
Budesonide Approved Phase 4 51333-22-3 63006 5281004
38
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
39
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
40
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
41
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
42
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
43
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
44
Zidovudine Approved Phase 4,Phase 3 30516-87-1 35370
45
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
46
Lopinavir Approved Phase 4 192725-17-0 92727
47
Trandolapril Approved Phase 4 87679-37-6 5484727
48
Verapamil Approved Phase 4 52-53-9 2520
49
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 98-92-0 936
50
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 1193)
# Name Status NCT ID Phase Drugs
1 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
2 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
3 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
4 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
5 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
6 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients (AGREEMENT) Unknown status NCT02932592 Phase 4
7 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
8 Effect of Medical Interventions in Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
9 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
10 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
11 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
12 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
13 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
14 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
15 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
16 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
17 Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT) Completed NCT01219231 Phase 4
18 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
19 The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes Completed NCT00546728 Phase 4 Exenatide;Metformin
20 Physical Exercise Versus Rosiglitazone in CAD and Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
21 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes Completed NCT01964703 Phase 4 Rubus occidentalis extract
22 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 Completed NCT01497132 Phase 4 Vitamin D3;Placebo
23 Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study) Completed NCT00928005 Phase 4
24 Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Completed NCT00241072 Phase 4 valsartan
25 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
26 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
27 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Completed NCT02167620 Phase 4 Metformin;Placebo
28 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
29 Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Completed NCT02617693 Phase 4
30 Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
31 Sitagliptin in Renal Transplant Recipients Completed NCT00740363 Phase 4 sitagliptin;placebo
32 Metformin and Longevity Genes in Prediabetes Completed NCT01765946 Phase 4 Metformin;placebo
33 Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes Completed NCT02754739 Phase 4 Pravastatin;Placebo (for Pravastatin)
34 The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol;HCTZ;Placebo
35 Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
36 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
37 Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients Completed NCT00319189 Phase 4 Nateglinide
38 Telmisartan and Losartan in Hypertensive IGT Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
39 The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes Completed NCT01181986 Phase 4 Exenatide SC;Exenatide IV;Placebo SC;Exendin-9;Placebo IV
40 Acarbose Cardiovascular Evaluation Trial Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
41 Acute Effect of Exenatide on Brain Glucose Metabolism Completed NCT01588418 Phase 4 Exenatide;Placebo
42 Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance Completed NCT00129233 Phase 4 Valsartan;Amlodipine
43 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
44 The Effect of Korean Red Ginseng Supplementation on Glucose Control Completed NCT01911663 Phase 4
45 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
46 Incretins in Impaired Fasting Glucose Completed NCT00364377 Phase 4 Sitagliptin
47 Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction Completed NCT00627744 Phase 4 Sitagliptin
48 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
49 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women Completed NCT00456885 Phase 4 exenatide;Placebo
50 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: glucose intolerance

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 29

Anatomical Context for Glucose Intolerance

MalaCards organs/tissues related to Glucose Intolerance:

41
Liver, Endothelial, Ovary, Testes, Heart, Spinal Cord, Kidney

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 1873)
# Title Authors Year
1
The deubiquitinating enzyme USP19 modulates adipogenesis and potentiates high-fat-diet-induced obesity and glucose intolerance in mice. ( 30386869 )
2019
2
High-fat diet induces a neurometabolic state characterized by changes in glutamate and N-acetylaspartate pools associated with early glucose intolerance: An in vivo multimodal MRI study. ( 29377412 )
2018
3
Postpartum risk of diabetes and predictive factors for glucose intolerance in East Asian women with gestational diabetes. ( 29596944 )
2018
4
Tau ablation in mice leads to pancreatic I^ cell dysfunction and glucose intolerance. ( 29401605 )
2018
5
Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD. ( 29666152 )
2018
6
Biomarkers of vascular injury and endothelial dysfunction after recent glucose intolerance in pregnancy. ( 29871496 )
2018
7
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet. ( 29401626 )
2018
8
Obesity: ANGPTL4 - the link binding obesity and glucose intolerance. ( 29611540 )
2018
9
Chaihu-shugan san inhibits inflammatory response to improve insulin signaling in liver and prefrontal cortex of CUMS rats with glucose intolerance. ( 29864926 )
2018
10
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain. ( 29364220 )
2018
11
Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes. ( 29590229 )
2018
12
Arsenic exposure induces glucose intolerance and alters global energy metabolism. ( 29118024 )
2018
13
Circulating B-type natriuretic peptide in women with and without recent gestational diabetes: The impact of current glucose intolerance. ( 29112786 )
2018
14
Ageing potentiates diet-induced glucose intolerance, I^-cell failure and tissue inflammation through TLR4. ( 29426925 )
2018
15
Correction: Intestinal Ralstonia pickettii augments glucose intolerance in obesity. ( 29381738 )
2018
16
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome. ( 29976929 )
2018
17
Wheat bran with enriched gamma-aminobutyric acid attenuates glucose intolerance and hyperinsulinemia induced by a high-fat diet. ( 29693103 )
2018
18
Grifola frondosa (Maitake) extract activates PPARI' and improves glucose intolerance in high-fat diet-induced obese mice. ( 29873587 )
2018
19
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
20
Association of the PCK2 Gene Polymorphism With New-onset Glucose Intolerance in Japanese Kidney Transplant Recipients. ( 29731064 )
2018
21
The Root of Atractylodes macrocephala Koidzumi Prevents Obesity and Glucose Intolerance and Increases Energy Metabolism in Mice. ( 29342124 )
2018
22
Unclassified hepatocellular adenoma in a middle-aged woman with glucose intolerance. ( 29116626 )
2018
23
Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intolerance. ( 29731256 )
2018
24
Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. ( 29842854 )
2018
25
Factors predicting early postpartum glucose intolerance in Japanese women with gestational diabetes mellitus: decision-curve analysis. ( 29706019 )
2018
26
Dietary yeast-derived mannan oligosaccharides have immune-modulatory properties but do not improve high fat diet-induced obesity and glucose intolerance. ( 29723205 )
2018
27
Sarcopoterium spinosum extract improved insulin sensitivity in mice models of glucose intolerance and diabetes. ( 29768504 )
2018
28
Glucose Intolerance ( 29763085 )
2018
29
Dihydrocapsiate supplementation prevented high-fat diet-induced adiposity, hepatic steatosis, glucose intolerance, and gut morphological alterations in mice. ( 29673543 )
2018
30
Chronic sleep disorder induced by psychophysiological stress induces glucose intolerance without adipose inflammation in mice. ( 29288667 )
2018
31
Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome. ( 29707577 )
2018
32
Blockade of Endothelin-1 Receptor Type B Ameliorates Glucose Intolerance and Insulin Resistance in a Mouse Model of Obstructive Sleep Apnea. ( 29896159 )
2018
33
Metformin Mitigates Fibrosis and Glucose Intolerance Induced by Doxorubicin in Subcutaneous Adipose Tissue. ( 29867463 )
2018
34
Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial. ( 30259623 )
2018
35
Glucose intolerance in children with cystic fibrosis: a developing country's perspective. ( 30244233 )
2018
36
Gestational diabetes mellitus in a multiethnic population in Spain: Incidence of and factors associated to impaired glucose tolerance one year after delivery. ( 30309812 )
2018
37
Proteoglycan 4 deficiency protects against glucose intolerance and fatty liver disease in diet-induced obese mice. ( 30448542 )
2018
38
Prevalence of glucose intolerance and metabolic syndrome within one year following delivery of a pregnancy complicated by gestational diabetes. ( 30505460 )
2018
39
Prevalence and Risk Factors for Glucose Intolerance among Saudi Women with Gestational Diabetes. ( 30186874 )
2018
40
One-hour oral glucose tolerance test plasma glucose at gestational diabetes diagnosis is a common predictor of the need for insulin therapy in pregnancy and postpartum impaired glucose tolerance. ( 29624902 )
2018
41
Associations between maternal triclosan concentrations in early pregnancy and gestational diabetes mellitus, impaired glucose tolerance, gestational weight gain and fetal markers of metabolic function. ( 29241065 )
2018
42
Maternal metabolic response to dietary treatment for impaired glucose tolerance and gestational diabetes mellitus. ( 29353417 )
2018
43
Predicting persistent impaired glucose tolerance in patients with gestational diabetes: The role of high sensitivity CRP and adiponectin. ( 29078256 )
2018
44
A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. ( 30097164 )
2018
45
Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. ( 30098324 )
2018
46
Glutathione S-transferase P Deficiency Induces Glucose Intolerance via JNK-dependent Enhancement of Hepatic Gluconeogenesis. ( 30153066 )
2018
47
Deletion of PHGDH in adipocytes improves glucose intolerance in diet-induced obese mice. ( 30180949 )
2018
48
Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. ( 30196334 )
2018
49
A Pediatric Case of Graves' Hyperthyroidism with Associated Glucose Intolerance Detected by a Urine Glucose Screening Program at School. ( 30224619 )
2018
50
Botryosphaeran reduces obesity, hepatic steatosis, dyslipidaemia, insulin resistance and glucose intolerance in diet-induced obese rats. ( 30227131 )
2018

Variations for Glucose Intolerance

ClinVar genetic disease variations for Glucose Intolerance:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 NC_012920.1: m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh38 Chromosome MT, 3243: 3243
2 MT-TL1 NC_012920.1: m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh37 Chromosome MT, 3243: 3243

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Pathways for Glucose Intolerance

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 ADIPOQ ADRB3 GCG INS INSR IRS1
2
Show member pathways
12.87 GCK IGF1 INS INSR IRS1 SLC2A4
3
Show member pathways
12.68 ADIPOQ INS INSR IRS1 LEP RBP4
4
Show member pathways
12.45 INS INSR IRS1 SLC2A4
5
Show member pathways
12.45 GCK INS IRS1 LEP LEPR
6
Show member pathways
12.43 IGF1 INS INSR IRS1
7 12.35 ADIPOQ GCG IGFBP1 INS INSR IRS1
8
Show member pathways
12.29 ADRB3 IGF1 INSR IRS1 PPARG
10
Show member pathways
12.22 ADIPOQ IGF1 INS INSR IRS1 LEP
11
Show member pathways
12.21 DPP4 GCG GHRL IGF1 INS LEP
12
Show member pathways
12.18 INS INSR IRS1 LEP SLC2A4
13
Show member pathways
12.09 ADIPOQ IGF1 INS INSR IRS1 PPARG
14
Show member pathways
12.05 IGF1 INS INSR IRS1 SLC2A4
15
Show member pathways
11.92 INS INSR IRS1 SLC2A4
16 11.83 IGF1 INS INSR
17
Show member pathways
11.78 ADIPOQ GCK INS INSR IRS1 SLC2A4
18 11.69 INS PPARG RBP4
19 11.69 ADIPOQ IRS1 LEP LEPR SLC2A4
20 11.68 ADIPOQ IGF1 INS IRS1 LEP PPARG
21 11.65 INS INSR IRS1
22 11.63 GCK IGFBP1 LEP
23 11.57 ADRB3 INS INSR IRS1
24
Show member pathways
11.56 DPP4 GCG LEP
25 11.54 IRS1 LEP LEPR SLC2A4
26 11.5 IGF1 INS INSR
27 11.47 INS INSR IRS1 LEP LEPR
28 11.45 GCK IGFBP1 INS
29 11.43 INS INSR IRS1
30 11.36 IGF1 INS INSR IRS1
31
Show member pathways
11.25 CRP LEP LEPR
32 11.23 INS INSR SLC2A4
33 11.15 ADIPOQ LEP PPARG
34
Show member pathways
10.94 INSR IRS1 SLC2A4
35 10.87 INS SLC2A4
36 10.44 ADIPOQ INSR IRS1 LEP PPARG SLC2A4

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ CRP GCG GHRL IGF1 IGFBP1
2 endoplasmic reticulum lumen GO:0005788 9.56 GCG GHRL IGFBP1 INS
3 secretory granule lumen GO:0034774 9.5 GCG GHRL INS
4 extracellular region GO:0005576 9.44 ADIPOQ CRP DPP4 GCG GHRL IGF1
5 insulin receptor complex GO:0005899 9.16 INSR IRS1

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.98 ADIPOQ GCG GHRL IGF1 INS LEP
2 carbohydrate metabolic process GO:0005975 9.96 ADRB3 GCK INS INSR SLC2A4
3 positive regulation of protein kinase B signaling GO:0051897 9.92 INS INSR IRS1 LEP
4 response to ethanol GO:0045471 9.88 ADIPOQ LEP RBP4 SLC2A4
5 response to nutrient GO:0007584 9.86 ADIPOQ LEP PPARG
6 positive regulation of MAPK cascade GO:0043410 9.85 ADRB3 IGF1 INS INSR LEP
7 response to insulin GO:0032868 9.84 IRS1 LEP RETN
8 insulin receptor signaling pathway GO:0008286 9.84 IGFBP1 INS INSR IRS1
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 IGF1 INS LEP
10 response to nutrient levels GO:0031667 9.82 ADIPOQ GHRL LEP
11 regulation of insulin secretion GO:0050796 9.81 DPP4 GCG GCK LEP
12 positive regulation of cold-induced thermogenesis GO:0120162 9.8 ADIPOQ ADRB3 GHRL LEP LEPR
13 positive regulation of insulin secretion GO:0032024 9.78 GCK GHRL RBP4
14 activation of protein kinase B activity GO:0032148 9.77 IGF1 INS INSR
15 glucose metabolic process GO:0006006 9.77 ADIPOQ GCK GHRL INS LEP
16 positive regulation of mitotic nuclear division GO:0045840 9.75 IGF1 INS INSR
17 cellular response to insulin stimulus GO:0032869 9.73 ADIPOQ GCK INSR IRS1 PPARG SLC2A4
18 positive regulation of glycolytic process GO:0045821 9.72 IGF1 INS INSR
19 positive regulation of cellular protein metabolic process GO:0032270 9.7 ADIPOQ INS
20 positive regulation of insulin receptor signaling pathway GO:0046628 9.7 INS IRS1 LEP
21 regulation of fat cell differentiation GO:0045598 9.69 LEP PPARG
22 fatty acid oxidation GO:0019395 9.69 ADIPOQ PPARG
23 insulin-like growth factor receptor signaling pathway GO:0048009 9.68 IGF1 IRS1
24 sexual reproduction GO:0019953 9.68 LEP LEPR
25 adult feeding behavior GO:0008343 9.68 GHRL LEP
26 cellular response to leptin stimulus GO:0044320 9.67 GCK LEP
27 negative regulation of blood vessel diameter GO:0097756 9.67 CRP INS
28 neuron projection maintenance GO:1990535 9.67 INS INSR
29 energy reserve metabolic process GO:0006112 9.67 ADRB3 LEP LEPR
30 leptin-mediated signaling pathway GO:0033210 9.65 LEP LEPR
31 negative regulation of lipid storage GO:0010888 9.65 CRP LEP
32 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.65 ADIPOQ CRP PPARG
33 negative regulation of acute inflammatory response GO:0002674 9.64 INS PPARG
34 negative regulation of feeding behavior GO:2000252 9.64 INS RETN
35 positive regulation of respiratory burst GO:0060267 9.63 INS INSR
36 regulation of bone remodeling GO:0046850 9.63 LEP LEPR
37 bone mineralization involved in bone maturation GO:0035630 9.62 IGF1 LEP
38 negative regulation of gluconeogenesis GO:0045721 9.62 ADIPOQ GCK INS LEPR
39 positive regulation of developmental growth GO:0048639 9.61 INSR LEP
40 bone growth GO:0098868 9.57 LEP LEPR
41 positive regulation of glucose import GO:0046326 9.55 ADIPOQ IGF1 INS INSR IRS1
42 positive regulation of glycogen biosynthetic process GO:0045725 9.35 GCK IGF1 INS INSR IRS1
43 glucose homeostasis GO:0042593 9.32 ADIPOQ GCK INS INSR IRS1 LEP
44 negative regulation of apoptotic process GO:0043066 10.09 GCG GHRL IGF1 INSR LEP
45 positive regulation of cell proliferation GO:0008284 10.08 DPP4 IGF1 INS INSR IRS1 LEP

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 ADIPOQ CRP DPP4 GCG INS LEPR
2 signaling receptor binding GO:0005102 9.72 ADIPOQ DPP4 GCG IGFBP1 LEP
3 insulin-like growth factor I binding GO:0031994 9.43 IGFBP1 INSR
4 insulin-like growth factor II binding GO:0031995 9.4 IGFBP1 INSR
5 insulin receptor binding GO:0005158 9.33 IGF1 INS IRS1
6 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS INSR IRS1
7 hormone activity GO:0005179 9.17 ADIPOQ GCG GHRL IGF1 INS LEP
8 protein binding GO:0005515 10.3 ADIPOQ ADRB3 CRP DPP4 GCG GCK

Sources for Glucose Intolerance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....